NSG 6005 PHARM MIDTERM TEST
QUESTIONS WITH THE CORRECT
ANSWERS
Nurse ipractitioner iprescriptive iauthority iis iregulated iby:
1. iThe iNational iCouncil iof iState iBoards iof iNursing
2. iThe iU.S. iDrug iEnforcement iAdministration
3. iThe iState iBoard iof iNursing ifor ieach istate
4. iThe iState iBoard iof iPharmacy i- icorrect ianswer-3. iThe iState iBoard iof iNursing ifor
ieach istate
The ibenefits ito ithe ipatient iof ihaving ian iAdvanced iPractice iRegistered iNurse
i(APRN) iprescriber iinclude:
1. iNurses iknow imore iabout iPharmacology ithan iother iprescribers ibecause ithey
itake iit iboth iin itheir ibasic inursing iprogram iand iin itheir iAPRN iprogram.
2. iNurses icare ifor ithe ipatient ifrom ia iholistic iapproach iand iinclude ithe ipatient iin
idecision imaking iregarding itheir icare.
3. iAPRNs iare iless ilikely ito iprescribe inarcotics iand iother icontrolled isubstances.
4. iAPRNs iare iable ito iprescribe iindependently iin iall istates, iwhereas ia iphysician's
iassistant ineeds ito ihave ia iphysician isupervising itheir ipractice. i- icorrect ianswer-2.
iNurses icare ifor ithe ipatient ifrom ia iholistic iapproach iand iinclude ithe ipatient iin
idecision imaking iregarding itheir icare.
Clinical ijudgment iin iprescribing iincludes:
1. iFactoring iin ithe icost ito ithe ipatient iof ithe imedication iprescribed
2. iAlways iprescribing ithe inewest imedication iavailable ifor ithe idisease iprocess
,3. iHanding iout idrug isamples ito ipoor ipatients
4. iPrescribing iall igeneric imedications ito icut icosts i- icorrect ianswer-1. iFactoring iin
ithe icost ito ithe ipatient iof ithe imedication iprescribed
Criteria ifor ichoosing ian ieffective idrug ifor ia idisorder iinclude:
1. iAsking ithe ipatient iwhat idrug ithey ithink iwould iwork ibest ifor ithem
2. iConsulting inationally irecognized iguidelines ifor idisease imanagement
3. iPrescribing imedications ithat iare iavailable ias isamples ibefore iwriting ia
iprescription
4. iFollowing iU.S. iDrug iEnforcement iAdministration iguidelines ifor iprescribing i-
icorrect ianswer-2. iConsulting inationally irecognized iguidelines ifor idisease
imanagement
Nurse ipractitioner ipractice imay ithrive iunder ihealth-care ireform ibecause iof:
1. iThe idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove
ipatient ioutcomes
2. iThe ifact ithat inurse ipractitioners iwill ibe iable ito ipractice iindependently
3. iThe ifact ithat inurse ipractitioners iwill ihave ifull ireimbursement iunder ihealth-care
ireform
4. iThe iability ito ishift iaccountability ifor iMedicaid ito ithe istate ilevel i- icorrect ianswer-
1. iThe idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove
ipatient ioutcomes
A ipatient's inutritional iintake iand ilaboratory iresults ireflect ihypoalbuminemia. iThis
is icritical ito iprescribing ibecause:
1. iDistribution iof idrugs ito itarget itissue imay ibe iaffected.
2. iThe isolubility iof ithe idrug iwill inot imatch ithe isite iof iabsorption.
3. iThere iwill ibe iless ifree idrug iavailable ito igenerate ian ieffect.
4. iDrugs ibound ito ialbumin iare ireadily iexcreted iby ithe ikidneys. i- icorrect ianswer-1.
iDistribution iof idrugs ito itarget itissue imay ibe iaffected.
Drugs ithat ihave ia isignificant ifirst-pass ieffect:
1. iMust ibe igiven iby ithe ienteral i(oral) iroute ionly
2. iBypass ithe ihepatic icirculation
,3. iAre irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction
4. iAre iconverted iby ithe iliver ito imore iactive iand ifat-soluble iforms i- icorrect ianswer-
3. iAre irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction
The iroute iof iexcretion iof ia ivolatile idrug iwill ilikely ibe ithe:
1. iKidneys
2. iLungs
3. iBile iand ifeces
4. iSkin i- icorrect ianswer-2. iLungs
Medroxyprogesterone i(Depo iProvera) iis iprescribed iintramuscularly i(IM) ito icreate ia
istorage ireservoir iof ithe idrug. iStorage ireservoirs:
1. iAssure ithat ithe idrug iwill ireach iits iintended itarget itissue
2. iAre ithe ireason ifor igiving iloading idoses
3. iIncrease ithe ilength iof itime ia idrug iis iavailable iand iactive
4. iAre imost icommon iin icollagen itissues i- icorrect ianswer-3. iIncrease ithe ilength iof
itime ia idrug iis iavailable iand iactive
The iNP ichooses ito igive icephalexin ievery i8 ihours ibased ion iknowledge iof ithe
idrug's:
1. iPropensity ito igo ito ithe itarget ireceptor
2. iBiological ihalf-life
3. iPharmacodynamics
4. iSafety iand iside ieffects i- icorrect ianswer-2. iBiological ihalf-life
Azithromycin idosing irequires ithat ithe ifirst iday's idosage ibe itwice ithose iof ithe iother
4 idays iof ithe iprescription. iThis iis iconsidered ia iloading idose. iA iloading idose:
1. iRapidly iachieves idrug ilevels iin ithe itherapeutic irange
2. iRequires ifour- ito ifive-half-lives ito iattain
3. iIs iinfluenced iby irenal ifunction
4. iIs idirectly irelated ito ithe idrug icirculating ito ithe itarget itissues i- icorrect ianswer-1.
iRapidly iachieves idrug ilevels iin ithe itherapeutic irange
, The ipoint iin itime ion ithe idrug iconcentration icurve ithat iindicates ithe ifirst isign iof ia
therapeutic ieffect iis ithe:
1. iMinimum iadverse ieffect ilevel
2. iPeak iof iaction
3. iOnset iof iaction
4. iTherapeutic irange i- icorrect ianswer-3. iOnset iof iaction
Phenytoin irequires ithat ia itrough ilevel ibe idrawn. iPeak iand itrough ilevels iare idone:
1. iWhen ithe idrug ihas ia iwide itherapeutic irange
2. iWhen ithe idrug iwill ibe iadministered ifor ia ishort itime ionly
3. iWhen ithere iis ia ihigh icorrelation ibetween ithe idose iand isaturation iof ireceptor
isites
4. iTo idetermine iif ia idrug iis iin ithe itherapeutic irange i- icorrect ianswer-4. iTo
idetermine iif ia idrug iis iin ithe itherapeutic irange
A ilaboratory iresult iindicates ithat ithe ipeak ilevel ifor ia idrug iis iabove ithe iminimum
toxic iconcentration. iThis imeans ithat ithe:
1. iConcentration iwill iproduce itherapeutic ieffects
2. iConcentration iwill iproduce ian iadverse iresponse
3. iTime ibetween idoses imust ibe ishortened
4. iDuration iof iaction iof ithe idrug iis itoo ilong i- icorrect ianswer-2. iConcentration iwill
iproduce ian iadverse iresponse
Drugs ithat iare ireceptor iagonists imay idemonstrate iwhat iproperty?
1. iIrreversible ibinding ito ithe idrug ireceptor isite
2. iUpregulation iwith ichronic iuse
3. iDesensitization ior idownregulation iwith icontinuous iuse
4. iInverse irelationship ibetween idrug iconcentration iand idrug iaction i- icorrect
ianswer-3. iDesensitization ior idownregulation iwith icontinuous iuse
Drugs ithat iare ireceptor iantagonists, isuch ias ibeta iblockers, imay icause:
QUESTIONS WITH THE CORRECT
ANSWERS
Nurse ipractitioner iprescriptive iauthority iis iregulated iby:
1. iThe iNational iCouncil iof iState iBoards iof iNursing
2. iThe iU.S. iDrug iEnforcement iAdministration
3. iThe iState iBoard iof iNursing ifor ieach istate
4. iThe iState iBoard iof iPharmacy i- icorrect ianswer-3. iThe iState iBoard iof iNursing ifor
ieach istate
The ibenefits ito ithe ipatient iof ihaving ian iAdvanced iPractice iRegistered iNurse
i(APRN) iprescriber iinclude:
1. iNurses iknow imore iabout iPharmacology ithan iother iprescribers ibecause ithey
itake iit iboth iin itheir ibasic inursing iprogram iand iin itheir iAPRN iprogram.
2. iNurses icare ifor ithe ipatient ifrom ia iholistic iapproach iand iinclude ithe ipatient iin
idecision imaking iregarding itheir icare.
3. iAPRNs iare iless ilikely ito iprescribe inarcotics iand iother icontrolled isubstances.
4. iAPRNs iare iable ito iprescribe iindependently iin iall istates, iwhereas ia iphysician's
iassistant ineeds ito ihave ia iphysician isupervising itheir ipractice. i- icorrect ianswer-2.
iNurses icare ifor ithe ipatient ifrom ia iholistic iapproach iand iinclude ithe ipatient iin
idecision imaking iregarding itheir icare.
Clinical ijudgment iin iprescribing iincludes:
1. iFactoring iin ithe icost ito ithe ipatient iof ithe imedication iprescribed
2. iAlways iprescribing ithe inewest imedication iavailable ifor ithe idisease iprocess
,3. iHanding iout idrug isamples ito ipoor ipatients
4. iPrescribing iall igeneric imedications ito icut icosts i- icorrect ianswer-1. iFactoring iin
ithe icost ito ithe ipatient iof ithe imedication iprescribed
Criteria ifor ichoosing ian ieffective idrug ifor ia idisorder iinclude:
1. iAsking ithe ipatient iwhat idrug ithey ithink iwould iwork ibest ifor ithem
2. iConsulting inationally irecognized iguidelines ifor idisease imanagement
3. iPrescribing imedications ithat iare iavailable ias isamples ibefore iwriting ia
iprescription
4. iFollowing iU.S. iDrug iEnforcement iAdministration iguidelines ifor iprescribing i-
icorrect ianswer-2. iConsulting inationally irecognized iguidelines ifor idisease
imanagement
Nurse ipractitioner ipractice imay ithrive iunder ihealth-care ireform ibecause iof:
1. iThe idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove
ipatient ioutcomes
2. iThe ifact ithat inurse ipractitioners iwill ibe iable ito ipractice iindependently
3. iThe ifact ithat inurse ipractitioners iwill ihave ifull ireimbursement iunder ihealth-care
ireform
4. iThe iability ito ishift iaccountability ifor iMedicaid ito ithe istate ilevel i- icorrect ianswer-
1. iThe idemonstrated iability iof inurse ipractitioners ito icontrol icosts iand iimprove
ipatient ioutcomes
A ipatient's inutritional iintake iand ilaboratory iresults ireflect ihypoalbuminemia. iThis
is icritical ito iprescribing ibecause:
1. iDistribution iof idrugs ito itarget itissue imay ibe iaffected.
2. iThe isolubility iof ithe idrug iwill inot imatch ithe isite iof iabsorption.
3. iThere iwill ibe iless ifree idrug iavailable ito igenerate ian ieffect.
4. iDrugs ibound ito ialbumin iare ireadily iexcreted iby ithe ikidneys. i- icorrect ianswer-1.
iDistribution iof idrugs ito itarget itissue imay ibe iaffected.
Drugs ithat ihave ia isignificant ifirst-pass ieffect:
1. iMust ibe igiven iby ithe ienteral i(oral) iroute ionly
2. iBypass ithe ihepatic icirculation
,3. iAre irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction
4. iAre iconverted iby ithe iliver ito imore iactive iand ifat-soluble iforms i- icorrect ianswer-
3. iAre irapidly imetabolized iby ithe iliver iand imay ihave ilittle iif iany idesired iaction
The iroute iof iexcretion iof ia ivolatile idrug iwill ilikely ibe ithe:
1. iKidneys
2. iLungs
3. iBile iand ifeces
4. iSkin i- icorrect ianswer-2. iLungs
Medroxyprogesterone i(Depo iProvera) iis iprescribed iintramuscularly i(IM) ito icreate ia
istorage ireservoir iof ithe idrug. iStorage ireservoirs:
1. iAssure ithat ithe idrug iwill ireach iits iintended itarget itissue
2. iAre ithe ireason ifor igiving iloading idoses
3. iIncrease ithe ilength iof itime ia idrug iis iavailable iand iactive
4. iAre imost icommon iin icollagen itissues i- icorrect ianswer-3. iIncrease ithe ilength iof
itime ia idrug iis iavailable iand iactive
The iNP ichooses ito igive icephalexin ievery i8 ihours ibased ion iknowledge iof ithe
idrug's:
1. iPropensity ito igo ito ithe itarget ireceptor
2. iBiological ihalf-life
3. iPharmacodynamics
4. iSafety iand iside ieffects i- icorrect ianswer-2. iBiological ihalf-life
Azithromycin idosing irequires ithat ithe ifirst iday's idosage ibe itwice ithose iof ithe iother
4 idays iof ithe iprescription. iThis iis iconsidered ia iloading idose. iA iloading idose:
1. iRapidly iachieves idrug ilevels iin ithe itherapeutic irange
2. iRequires ifour- ito ifive-half-lives ito iattain
3. iIs iinfluenced iby irenal ifunction
4. iIs idirectly irelated ito ithe idrug icirculating ito ithe itarget itissues i- icorrect ianswer-1.
iRapidly iachieves idrug ilevels iin ithe itherapeutic irange
, The ipoint iin itime ion ithe idrug iconcentration icurve ithat iindicates ithe ifirst isign iof ia
therapeutic ieffect iis ithe:
1. iMinimum iadverse ieffect ilevel
2. iPeak iof iaction
3. iOnset iof iaction
4. iTherapeutic irange i- icorrect ianswer-3. iOnset iof iaction
Phenytoin irequires ithat ia itrough ilevel ibe idrawn. iPeak iand itrough ilevels iare idone:
1. iWhen ithe idrug ihas ia iwide itherapeutic irange
2. iWhen ithe idrug iwill ibe iadministered ifor ia ishort itime ionly
3. iWhen ithere iis ia ihigh icorrelation ibetween ithe idose iand isaturation iof ireceptor
isites
4. iTo idetermine iif ia idrug iis iin ithe itherapeutic irange i- icorrect ianswer-4. iTo
idetermine iif ia idrug iis iin ithe itherapeutic irange
A ilaboratory iresult iindicates ithat ithe ipeak ilevel ifor ia idrug iis iabove ithe iminimum
toxic iconcentration. iThis imeans ithat ithe:
1. iConcentration iwill iproduce itherapeutic ieffects
2. iConcentration iwill iproduce ian iadverse iresponse
3. iTime ibetween idoses imust ibe ishortened
4. iDuration iof iaction iof ithe idrug iis itoo ilong i- icorrect ianswer-2. iConcentration iwill
iproduce ian iadverse iresponse
Drugs ithat iare ireceptor iagonists imay idemonstrate iwhat iproperty?
1. iIrreversible ibinding ito ithe idrug ireceptor isite
2. iUpregulation iwith ichronic iuse
3. iDesensitization ior idownregulation iwith icontinuous iuse
4. iInverse irelationship ibetween idrug iconcentration iand idrug iaction i- icorrect
ianswer-3. iDesensitization ior idownregulation iwith icontinuous iuse
Drugs ithat iare ireceptor iantagonists, isuch ias ibeta iblockers, imay icause:
